Pfizer is licensing a pre-clinical therapy for patients with rare autoimmune conditions, paying $25 million upfront for what the company sees as a potentially better alternative to a treatment derived from human blood plasma.
The big drug maker signed an exclusive global licensing deal with Baltimore, Maryland-based startup Gliknik for the drug candidate stradomer,...


![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)

